Abstract
The combined 5-year survival rate for all newly diagnosed gastric cancer patients in the United States is about 24 % [1]. The mortality rate is high because two-thirds of Americans initially present with TNM stage III–IV disease, not only making it more difficult to achieve resection with uninvolved margins, but also increasing the probability of systemic spread. Cure is only achieved through a combination of gastrectomy and lymphadenectomy with or without neo-adjuvant and/or perioperative chemotherapy. In the USA, only about one-quarter of newly diagnosed patients undergo curative-intent resection [2]. Though this intervention undoubtedly improves the prognosis, it is by no means a panacea, as the 5-year survival rate of patients treated with curative intent is 47–60 % and recurrence occurs in 15–37 % [3] (Table 20.1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;2:71–96.
Wanebo HJ, Kennedy BJ, Chmiel J, Steele Jr G, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;5:583–92.
Samson PS, Escovidal LA, Yrastorza SG, Veneracion RG, Nerves MY. Re-study of gastric cancer: analysis of outcome. World J Surg. 2002;26:428–33.
Nashimoto A, Yabusaki H, Nakagawa S. Evaluation and problems of follow-up surveillance after curative gastric cancer surgery. Nippon Geka Gakkai Zasshi. 2007;108:120–4.
Wu B, Wu D, Wang M, Wang G. Recurrence in patients following curative resection of early gastric carcinoma. J Surg Oncol. 2008;98:411–4.
Tan IT, So BYJ. Value of intensive follow-up of patients after curative surgery for gastric carcinoma. J Surg Oncol. 2007;96:503–6.
Whiting J, Sano T, Saka M, Fukagawa T, Katai H, Sasako M. Follow-up of gastric cancer: a review. Gastric Cancer. 2006;9:74–81.
Sakar B, Karagol H, Gumus M, Basaran M, Kaytan E, Argon A, et al. Timing of death from tumor recurrence after curative gastrectomy for gastric cancer. Am J Clin Oncol. 2004;27:205–9.
Bennett JJ, Gonen M, D’Angelica M, Jaques DP, Brennan MF, Coit DG. Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer? J Am Coll Surg. 2005;201:503–10.
Deng JY, Liang H, Sun D, Zhan H, Wang X. The most appropriate category of metastatic lymph nodes to evaluate overall survival of gastric cancer following curative resection. J Surg Oncol. 2008;98:343–8.
Marchet A, Mocellin S, Ambrosi A, De Manzoni G, Di Leo A, Marrelli D, et al. The prognostic value of N-ratio in patients with gastric cancer: validation in a large, multicenter series. Eur J Surg Oncol. 2008;34:159–65.
Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S. Multivariate prognostic study on large gastric cancer. J Surg Oncol. 2007;96:14–8.
Marrelli D, De Stefano A, De Manzoni G, Morgagni P, Di Leo A, Roviello F. A scoring system obtained from a prospective multicenter study. Ann Surg. 2005;241:247–55.
Marrelli D, Pinto E, De Stafano A, Farnetani M, Garosi L, Roviello F. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001;181:16–9.
Patriti A, Graziosi L, Baffa N, Pacifico E, Lamprini P, Valiani S, et al. Postoperative follow-up of gastric adenocarcinoma with neoplastic markers and 18-FDG-PET/CT. Ann Ital Chir. 2007;78:481–5.
Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, et al. The usefulness of CEA and/or CA 19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142–5.
Shimizu N, Yamashiro H, Murakami A, Hamazoe R, Maeta M. Diagnostic accuracy of a combination of assays for immunosuppressive acidic protein and carcinoembryonic antigen in detection of recurrence of gastric cancer. Eur J Cancer. 1991;27:190–3.
Joypaul B, Browning M, Newman E, Byrne D, Cuschieri A. Comparison of serum CA 72-4 and CA 19-9 levels in gastric cancer patients and correlation with recurrence. Am J Surg. 1995;169:595–9.
Chan AOO, Chu K, Lam SK, Cheung KL, Law S, Kwok K, et al. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. Cancer. 2005;104:740–6.
National Comprehensive Cancer (#6) AND (specificity[Title/Abstract]) AND (gastric[title]) Network (2009) Gastric Cancer NCCN Clinical Practice Guidelines in Oncology v.2.2009.
De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med. 2002;29:525–9.
Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003;44:690–9.
Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: a systematic review and meta-analysis of randomized trials. Br Med J. 2002;324:813–6.
Bohner H, Zimmer T, Hopfenmuller W, Berger G, Buhr HJ. Detection and prognosis of recurrent gastric cancer—is routine follow-up after gastrectomy worthwhile? Hepatogastroenterology. 2000;47:1489–94.
Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol. 2003;10:898–902.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Humana Press
About this chapter
Cite this chapter
Coleman, A., Tyler, D. (2013). Stomach Carcinoma Surveillance Counterpoint: USA. In: Johnson, F., et al. Patient Surveillance After Cancer Treatment. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-969-7_20
Download citation
DOI: https://doi.org/10.1007/978-1-60327-969-7_20
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-968-0
Online ISBN: 978-1-60327-969-7
eBook Packages: MedicineMedicine (R0)